share_log

Repare Therapeutics Receives $1.5M Payment From Ono Pharmaceuticals

Repare Therapeutics Receives $1.5M Payment From Ono Pharmaceuticals

瑞普雷療法從大野製藥獲得 1.5 萬美元的付款
Benzinga Real-time News ·  2023/01/19 07:08

Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced that the Company has received an approximately $1.5 million (¥200 million) research service payment from Ono Pharmaceutical Co., Ltd. ("Ono"). The payment reflects achievement of a specified research trigger, under the companies' 2019 Strategic Partnership Agreement ("Ono Agreement"). Under the terms of the Ono Agreement, Repare is primarily responsible for carrying out research activities for its Polθ program, now known as RP-2119, until the first submission of an IND in the U.S. or Japan.

亞洲網加利福尼亞州聖約瑟10月23日電臨床階段精確腫瘤學領先公司Repare治療公司(以下簡稱Repare或公司)(納斯達克代碼:Rptx)今天宣佈,該公司已從小野製藥有限公司(以下簡稱小野製藥)獲得約150萬美元(約合人民幣2億元)的研究服務金。這筆付款反映了根據兩家公司的2019年戰略合作夥伴協定(“小野協定”),完成了一項特定的研究觸發因素。根據小野協定的條款,在美國或日本首次提交IND之前,REPARE主要負責其POLθ計劃(現在稱為RP-2119)的研究活動。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論